Novo Nordisk launches subscription for obesity drugs
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Novo Nordisk announced it will sell its obesity drugs at a lower cash price to patients subscribing through certain telehealth providers.
- The new subscription plan aims to make Novo Nordisk's obesity medications more accessible while integrating telehealth services into the purchasing process.
- The pharma-telehealth tie-up is prompting discussions regarding the evolving landscape of drug distribution and patient access models.
Why it matters: Novo Nordisk's new subscription model could alter drug access for patients using telehealth providers.
